Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2017-01-11 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
关于转让天津昂赛细胞基因工程有限公司38%股权完成工商变更登记的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (473 characters) regarding the completion of a share transfer and related business registration changes. It details the transfer of 38% equity of a subsidiary company and confirms the completion of the registration process. There is no financial data, no detailed report, no meeting materials, or voting results. It is an official announcement about a capital/ownership change related to shareholding in a subsidiary. This fits best under Capital/Financing Update (CAP) as it concerns a financing/capital structure event (equity transfer). The document is not a full report, nor a regulatory filing or announcement of a report. Therefore, the classification is CAP with high confidence.
2017-01-11 Chinese
关于对上海证券交易所问询函回复的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from 中源协和细胞基因工程股份有限公司 responding to an inquiry from the Shanghai Stock Exchange regarding a related party acquisition transaction. It contains extensive financial forecasts, valuation assumptions, and an asset valuation report using the income approach (收益法). The document includes detailed financial projections, assumptions on revenue, costs, discount rates (WACC), and risk factors. It also provides a comprehensive asset valuation summary and explanations of valuation methods and assumptions. The content is focused on the valuation and financial analysis related to a specific transaction rather than a full annual or interim report. It is not a simple announcement or a brief summary but a substantive disclosure of valuation and financial data related to a capital transaction and regulatory inquiry. This fits best with the category of Capital/Financing Update (CAP), as it relates to a significant financing-related transaction (acquisition of equity in a subsidiary) and includes detailed financial and valuation information supporting that transaction. It is not an Annual Report (10-K), Interim Report (IR), or Audit Report (AR), nor is it a Regulatory Filing (RNS) because it contains detailed financial data and valuation analysis rather than just a certification or announcement. Therefore, the classification is CAP with high confidence.
2017-01-10 Chinese
协和干细胞基因工程有限公司拟收购协和华东干细胞基因工程有限公司股权项目资产评估报告书
Regulatory Filings
2017-01-10 Chinese
关于子公司协和干细胞基因工程有限公司与天津滨海协和投资有限公司签署业绩补偿协议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a performance compensation agreement between a subsidiary and an affiliated party related to an acquisition and associated profit guarantees. It details the terms of the agreement, compensation principles, and procedures for profit shortfalls and impairment testing. The document is a formal announcement of a corporate transaction and related agreement, not a financial report, audit, or earnings release. It does not contain financial statements or detailed financial analysis but rather discloses a specific corporate event and contractual arrangement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2017-01-10 Chinese
2017年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the "2017 First Extraordinary General Meeting" of Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It contains detailed meeting agenda, voting procedures, and multiple proposals for shareholder approval. The proposals include acquisition of a subsidiary's equity, related party transactions, loan applications by a subsidiary, and guarantees for loans. The document is structured as meeting materials for a shareholder meeting, including agenda, voting instructions, and detailed explanations of proposals to be voted on. There is no indication that this is a full annual or interim report, earnings release, or other financial report. It is not a simple announcement of voting results but the materials provided for the meeting itself. Therefore, this document fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting.
2017-01-10 Chinese
关于2017年第一次临时股东大会增加临时提案的公告
Regulatory Filings Classification · 90% confidence The document is an announcement regarding the addition of temporary proposals to the agenda of the 2017 first extraordinary general meeting of shareholders. It details the meeting date, voting procedures, and specific proposals related to loans and guarantees involving subsidiaries. It does not contain financial statements or detailed financial analysis but rather informs shareholders about meeting agenda changes and voting arrangements. The document length is 2374 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or a related shareholder meeting announcement. However, since it is about adding proposals to a shareholder meeting and not the voting results themselves, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about shareholder meeting agenda changes and not the voting results or the meeting materials themselves.
2017-01-06 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.